Lymphoma survivors experience high bankruptcy rates

The high cost of contemporary cancer care does not usually include legal fees paid to personal bankruptcy lawyers but perhaps they should. According to recent research out of the Fred Hutchinson Cancer Research Center in Seattle, five years after diagnosis, cancer patients were four times as likely to declare bankruptcy than the general public.

In absolute statistics, 0.28 % of the general public declared bankruptcy in Washington state between 1995 and 2009, compared to 1.9% of cancer patients during the same time frame.

Researchers also found that some cancers tend to lead to bankruptcy more than others. The top five cancers, listed in their order from the top, were:

-- Lung cancer
-- Thyroid cancer
-- Lymphoma & Leukemia
-- Uterine cancer
-- Colorectal cancer

The study's authors did not have direct evidence explaining why these cancers were more commonly associated with bankruptcy filing, but they did speculate on some possible reasons.

With regard to lymphoma and leukemia, the authors wrote that this was most likely due to the extraordinarily high treatment costs, treatment which in many cases amount to a bone marrow transplantation—a procedure that, alone, can run into the low hundreds of thousands of dollars.

Source

Ramsey SD et al. Cancer diagnosis as a risk factor for personal bankruptcy. Abstract 6007, 2011 ASCO Annual Meeting.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap